Skip to main content

Table 1 Patient characteristics at admission

From: Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma

Parameters

Data

Male, n (%)

25 (86.2%)

Mean age, years

59.2 ± 11.3

Lesion types

 Right liver

16 (55.2%)

 Left liver

2 (6.9%)

 Whole liver

11 (37.9%)

Median duration of symptom, months

1.0 (0.6, 6.0)

Recurrent/unresectable HCC

4 (13.8%)/25 (86.2%)

Systemic chemotherapy

1 (3.4%)

Targeted therapy

13 (44.8%)

Etiology HBV/HCV

25 (86.2%)/2 (6.9%)

BCLC stage B/C

7 (24.1%)/22 (75.9%)

Child–Pugh class A/B

22 (75.9%)/7 (24.1%)

One/two/multiple tumors

15 (51.7%)/4 (13.8%)/10 (34.5%)

Portal venous tumor emboli

9 (31.0%)

Local or distant metastasis

14 (48.3%)/3 (10.3%)

Tumor diameter, mm

91.6 ± 41.2

  1. HBV Hepatitis B Virus, HCV Hepatitis C Virus, BCLC Barcelona Clinic Liver Cancer